Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Operating Expenses (2020 - 2026)

Climb Bio filings provide 7 years of Operating Expenses readings, the most recent being $15.2 million for Q1 2026.

  • Quarterly Operating Expenses fell 33.92% to $15.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $60.1 million through Mar 2026, down 41.12% year-over-year, with the annual reading at $67.9 million for FY2025, 17.24% down from the prior year.
  • Operating Expenses hit $15.2 million in Q1 2026 for Climb Bio, down from $19.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $56.4 million in Q2 2024 and bottomed at $3.0 million in Q1 2024.
  • Average Operating Expenses over 5 years is $14.7 million, with a median of $11.7 million recorded in 2024.
  • Peak annual rise in Operating Expenses hit 739.62% in 2024, while the deepest fall reached 87.18% in 2024.
  • Climb Bio's Operating Expenses stood at $9.6 million in 2022, then plummeted by 46.39% to $5.1 million in 2023, then surged by 113.02% to $10.9 million in 2024, then soared by 76.85% to $19.3 million in 2025, then dropped by 21.17% to $15.2 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Operating Expenses are $15.2 million (Q1 2026), $19.3 million (Q4 2025), and $14.9 million (Q3 2025).